🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

518 results for “Cho” Clear

  1. PRAX-222

    Chongqing Precision Biotech Co., Ltd

    Voltage-gated sodium channel type II alpha subunit (SCN2A) developmental and epileptic encephalopathy (DEE)

    phase 3 small molecule active

    1 trial

  2. PRAX-562

    Chongqing Precision Biotech Co., Ltd

    SCN2A Encephalopathy

    phase 3 small molecule active

    1 trial

  3. PRAX-628, PRAX-628, PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal onset seizures or primary generalized tonic-clonic seizures.

    phase 3 small molecule active

    1 trial

  4. PRAX-628, PRAX-628, Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  5. PROTAMINE CHOAY 1000 U.A.H./ml, solution injectable

    Pari Pharma GmbH

    Any patients ≥18 years old, eligible for transfemoral TAVI with coverage for medical insurance

    phase 3 small molecule active

    1 trial

  6. Paeoniflorin + phosphatidylcholine or silymarin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hepatitis, Autoimmune

    phase 3 small molecule terminated

    1 trial

  7. Pemazyre 9 mg tablets, Pemazyre 13.5 mg tablets, Pemazyre 4.5 mg tablets, Gemcitabine 1000 mg, powder for solution for infusion, Cisplatin Ebewe 1 mg/ml – Konzentrat zur Herstellung einer Infusionslösung

    Incyte

    Cholangiocarcinoma

    phase 3 small molecule active

    1 trial

  8. Pemigatinib

    Incyte

    Unresectable Cholangiocarcinoma

    phase 3 small molecule terminated

    1 trial

  9. Pimavanserin tartrate (ACP-103)

    Acadia Pharmaceuticals B.V.

    Parkinson's Disease Psychosis

    phase 3 small molecule completed

    4 trials

  10. Placebo

    Regeneron UK Limited

    Heterozygous Familial Hypercholesterolemia

    phase 3 small molecule completed

    1 trial

  11. Placebo

    Acadia Pharmaceuticals B.V.

    Dementia-related Psychosis

    phase 3 small molecule completed

    1 trial

  12. Placebo (for alirocumab)

    Regeneron UK Limited

    Hypercholesterolemia

    phase 3 small molecule completed

    5 trials

  13. Placebo efgartigimod IV concentrate for solution, ARGX-113, Vyvgart 20 mg/mL concentrate for solution for infusion

    argenx

    Acetylcholine Receptor Binding Antibody Seronegative Generalized Myasthenia Gravis

    phase 3 small molecule active

    1 trial

  14. Placebo for MK-0616, Placebo for Ezetimibe, EZETIMIBE , BEMPEDOIC ACID , MK-0616, Placebo for Bempedoic Acid

    Merck Sharp and Dohme

    Hypercholesterolemia

    phase 3 small molecule active

    1 trial

  15. Placebo for PRAX-628, PRAX-628

    Chongqing Precision Biotech Co., Ltd

    Focal Epilepsy

    phase 3 small molecule active

    1 trial

  16. Placebo matching Obicetrapib 10 mg tablets, Obicetrapib, Placebo matching Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC) tablets, Obicetrapib 10 mg + ezetimibe 10 mg fixed dose combination (FDC)

    Lacuna Pharma Pty Ltd

    Adults with Type 2 Diabetes and/or Metabolic Syndrome on guideline recommended lipid lowering therapy and elevated low-density lipoprotein cholesterol (LDL-C)

    phase 3 small molecule active

    1 trial

  17. Placebo of Zodasiran, ARO-ANG3

    Arrowhead Pharmaceuticals Ireland Limited

    Homozygous Familial Hypercholesterolemia (HoFH)

    phase 3 small molecule active

    1 trial

  18. Placebo to match 10 mg, Placebo to match 5 mg

    Gilead Sciences Pty Limited

    Primary Biliary Cholangitis

    phase 3 small molecule active

    1 trial

  19. Placebo to match Choline Chloride for Injection, Choline Chloride for Injection

    Protara Therapeutics

    Intestinal Failure

    phase 3 small molecule active

    1 trial

  20. Placebo, oral solution, Maralixibat chloride

    Lacuna Pharma Pty Ltd

    Cholestatic Pruritus

    phase 3 small molecule active

    1 trial

  21. Policosanol

    BRIGHT MINDS BIOSCIENCES INC.

    Hypercholesterolemia

    phase 3 small molecule terminated

    1 trial

  22. REN001

    OnKure Therapeutics

    Primary Mitochondrial Myopathy

    phase 3 small molecule terminated

    2 trials

  23. Recombinant Respiratory Syncytial Virus Vaccine (CHO Cell)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Respiratory Syncytial Virus (RSV)

    phase 3 mab active

    1 trial

  24. Rilvegostomig, TEGAFUR, GLUCOSE, INFLIXIMAB, CAPECITABINE, CISPLATIN, MYCOPHENOLATE MOFETIL, TEGAFUR, CAPECITABINE, GEMCITABINE, SODIUM CHLORIDE

    AstraZeneca AB

    Adenocarcinoma of the biliary tract (intrahepatic or extrahepatic cholangiocarcinoma or muscle invasive gallbladder cancer GBC)

    phase 3 small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources